ClinicalTrials.Veeva

Menu

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

Sanofi logo

Sanofi

Status and phase

Completed
Phase 3

Conditions

Obesity
Dyslipidemia

Treatments

Drug: Rimonabant (SR141716)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00029835
EFC4735

Details and patient eligibility

About

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

Enrollment

1,033 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

  • BMI must be greater than 27 and less than 40
  • Patients with untreated dyslipidemia
  • Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

35

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems